High serum C-reactive protein levels predict survival in patients with treated advanced lung adenocarcinoma.

ABSTRACT:

Background

The prognosis of non-small cell lung cancer (NSCLC) varies greatly depending on whether or not it can receive molecular-targeted drug treatment including epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). We investigated the clinical utility of C-reactive protein (CRP) levels measured at the time of diagnosis in EGFR-mutant and wild-type NSCLC patients who had undergone first-line therapy.

Methods

Serum CRP levels were analyzed in 213 patients, of whom 89 patients had advanced EGFR-mutated NSCLC who underwent first-line EGFR-TKI treatment. We used Cox proportional hazards models to study the relationship between CRP and overall survival (OS). CRP cutoff values were obtained from the receiver operating characteristic curve.

Results

Me

SUBMITTER: Hotta T 

PROVIDER: S-EPMC8024849 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature